COEUR D’ALENE, Idaho — In patients with dry age-related macular degeneration, the implantation of human embryonic stem cell-derived retinal pigment epithelial cells was mostly well tolerated, according to a poster presented at the Women in Ophthalmology Summer Symposium.
Ghesal Razag and colleagues sought to evaluate the safety and tolerability of OpRegen (Lineage Cell Therapeutics) in a dose-escalating phase 1/2a clinical trial in patients with advanced dry AMD accompanied by geographic atrophy.
The researchers reported safety data from the first 15 patients with at least 3 years
Uncategorized